RightFit
RecruitingPhase not listed

iDose TR Administration in an Office-Based Surgery Setting

Real-World Evidence Observational Study to Evaluate the Safety of iDose® TR (Travoprost Intracameral Implant) 75 µg in an Office-Based Surgery Setting

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study looks at giving iDose TR, a small implant that releases the drug travoprost inside the eye, during surgery in a doctor's office. It is for people with open-angle glaucoma, a disease that damages the eye's main nerve, or ocular hypertension, which means high pressure in the eye.

Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Have open-angle glaucoma or high pressure in the eye.

Who can't join

  • Have already received iDose TR or an experimental implant inside the eye being studied.
  • Have an active eye infection or inflammation (swelling or irritation).
  • Have a history of an allergic reaction to travoprost or materials in the implant.
  • Have had recent eye surgery.
  • Have a disease affecting the body that is not under control.
  • Have any condition that makes placing the implant unsafe.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT) Exclusion Criteria: * Prior administration of iDose TR or administration of an investigational intracameral implant in the study eye * Active ocular infection or inflammation * History of hypersensitivity to travoprost or implant components * Recent ocular surgery * Uncontrolled systemic disease * Any condition preventing safe implantation

Study sites (1)

TX